Compliance Requirements From the Pharmacovigilance and Vigilance Perspective, Upcoming Webinar Hosted by Xtalks


It is important for medical device companies to understand the latest requirements in the EU MDR, to minimize the risk of non-compliance and inability to certify products in the EU.

Companies attempting to comply with Medical Device Regulation (EU) 2017/745 (MDR), introduced in May 2021 for medical device certification in the EU are challenged by the complexity and scope of the requirements. It is important for medical device companies to understand the latest requirements in the EU MDR, to minimize the risk of non-compliance and inability to certify products in the EU.

Register to gain a clear understanding of the essential EU MDR requirements for medical device registration and vigilance.

Join Aarekh Shrestha, Sr. Manager and Head of Drug Safety/Device Vigilance, Veranex DM&A; and Garima Tripathi, Sr. Drug Safety Physician, Veranex, for the live webinar on Tuesday, March 14, 2023, at 2pm GMT (3pm CET/EU-Central).

For more information, or to register for this event, visit EU MDR: Compliance Requirements From the Pharmacovigilance and Vigilance Perspective.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Leave a Reply